CI RSI Chart
Last 7 days
-2.7%
Last 30 days
-3.0%
Last 90 days
4.5%
Trailing 12 Months
32.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 206.0B | 0 | 0 | 0 |
2023 | 183.0B | 186.1B | 189.9B | 195.3B |
2022 | 177.1B | 179.5B | 180.4B | 180.5B |
2021 | 162.9B | 166.8B | 170.1B | 174.1B |
2020 | 154.1B | 154.5B | 156.9B | 160.4B |
2019 | 75.2B | 102.5B | 129.6B | 153.6B |
2018 | 42.8B | 43.9B | 45.0B | 48.6B |
2017 | 40.3B | 40.8B | 41.3B | 41.8B |
2016 | 0 | 0 | 0 | 39.8B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 24, 2024 | ozuah philip | acquired | - | - | 539 | - |
Apr 24, 2024 | granger elder | acquired | - | - | 539 | - |
Apr 24, 2024 | kurian george | acquired | - | - | 539 | - |
Apr 24, 2024 | ross kimberly a. | acquired | - | - | 539 | - |
Apr 24, 2024 | foss eric j | acquired | - | - | 539 | - |
Apr 24, 2024 | delaney william j iii | acquired | - | - | 539 | - |
Apr 24, 2024 | mcclellan mark b. | acquired | - | - | 539 | - |
Apr 24, 2024 | zarcone donna f | acquired | - | - | 539 | - |
Apr 24, 2024 | mazzarella kathleen m | acquired | - | - | 539 | - |
Apr 24, 2024 | hathi neesha | acquired | - | - | 539 | - |
Which funds bought or sold CI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | HYMAN CHARLES D | added | 0.06 | 750,000 | 4,261,000 | 0.24% |
May 07, 2024 | Malaga Cove Capital, LLC | sold off | -100 | -2,733,980 | - | -% |
May 07, 2024 | Swiss National Bank | reduced | -5.32 | 41,122,500 | 318,264,000 | 0.22% |
May 07, 2024 | NorthRock Partners, LLC | added | 12.48 | 220,228 | 825,139 | 0.07% |
May 07, 2024 | Donoghue Forlines LLC | reduced | -19.04 | -12,589 | 682,434 | 0.19% |
May 07, 2024 | Bank Pictet & Cie (Europe) AG | added | 1.37 | 2,781,340 | 14,902,800 | 0.39% |
May 07, 2024 | BANK PICTET & CIE (ASIA) LTD | reduced | -4.15 | 84,439 | 603,985 | 0.05% |
May 07, 2024 | Empirical Financial Services, LLC d.b.a. Empirical Wealth Management | added | 13.53 | 1,922,310 | 7,022,640 | 0.21% |
May 07, 2024 | ClariVest Asset Management LLC | reduced | -70.34 | -9,238,780 | 5,189,620 | 0.54% |
May 07, 2024 | Abbrea Capital, LLC | unchanged | - | 60,000 | 338,000 | 0.04% |
Unveiling Cigna Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Cigna Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 463.9B | 371.6B | 20.73 | 1.25 | ||||
CI | 98.7B | 206.0B | 25.6 | 0.48 | ||||
HCA | 81.0B | 66.7B | 14.81 | 1.21 | ||||
CVS | 68.9B | 360.9B | 9.41 | 0.19 | ||||
CNC | 40.5B | 155.5B | 14.8 | 0.26 | ||||
DVA | 11.9B | 12.3B | 14.61 | 0.97 | ||||
UHS | 11.4B | 14.7B | 13.95 | 0.78 | ||||
MID-CAP | ||||||||
CHE | 8.7B | 2.3B | 30.56 | 3.78 | ||||
ACHC | 6.1B | 3.0B | -542.41 | 2.05 | ||||
AMN | 2.3B | 3.8B | 10.84 | 0.6 | ||||
AMEH | 2.1B | 1.4B | 34.78 | 1.52 | ||||
SMALL-CAP | ||||||||
ADUS | 1.8B | 1.1B | 26.7 | 1.61 | ||||
BKD | 1.4B | 3.0B | -7.76 | 0.44 | ||||
BEAT | 55.0M | - | -3.76 | - | ||||
AMS | 19.3M | 21.3M | 36.22 | 0.91 |
Cigna Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 12.0% | 57,255 | 51,114 | 49,048 | 48,586 | 46,517 | 45,753 | 45,281 | 45,478 | 44,006 | 45,679 | 44,288 | 43,131 | 40,971 | 41,712 | 40,955 | 39,265 | 38,469 | 38,245 | 38,556 | 38,819 | 37,946 |
S&GA Expenses | -8.8% | 3,705 | 4,062 | 3,788 | 3,434 | 3,538 | 3,484 | 3,151 | 3,264 | 3,275 | 3,644 | 3,093 | 2,996 | 3,279 | 3,966 | 3,301 | 3,407 | 3,398 | 3,957 | 3,413 | 3,380 | 3,303 |
EBITDA Margin | -19.8% | 0.04* | 0.05* | 0.06* | 0.07* | 0.07* | 0.07* | 0.07* | 0.06* | 0.06* | 0.06* | 0.09* | 0.09* | - | - | - | - | - | - | - | - | - |
Interest Expenses | 8.0% | 336 | 311 | 387 | 310 | 322 | 306 | 308 | 307 | 308 | 303 | 311 | 308 | 331 | 327 | 369 | 348 | 395 | 388 | 392 | 488 | 377 |
Income Taxes | 131.7% | 291 | -919 | 391 | 374 | 295 | 136 | 713 | 411 | 355 | 182 | 424 | 422 | 342 | 1,236 | 406 | 529 | 208 | 277 | 409 | 348 | 416 |
Earnings Before Taxes | -58.0% | 79.00 | 188 | 1,840 | 1,884 | 1,601 | 1,358 | 3,491 | 1,981 | 1,567 | 1,320 | 2,059 | 1,898 | 1,513 | 5,378 | 1,804 | 2,289 | 1,397 | 1,261 | 1,763 | 1,758 | 1,788 |
EBT Margin | -31.4% | 0.02* | 0.03* | 0.04* | 0.04* | 0.05* | 0.05* | 0.05* | 0.04* | 0.04* | 0.04* | 0.06* | 0.06* | - | - | - | - | - | - | - | - | - |
Net Income | -119.2% | -212 | 1,107 | 1,449 | 1,510 | 1,306 | 1,222 | 2,778 | 1,570 | 1,212 | 1,138 | 1,635 | 1,476 | 1,171 | 4,142 | 1,398 | 1,760 | 1,189 | 977 | 1,354 | 1,410 | 1,372 |
Net Income Margin | -32.0% | 0.02* | 0.03* | 0.03* | 0.04* | 0.04* | 0.04* | 0.04* | 0.03* | 0.03* | 0.03* | 0.05* | 0.05* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 229.9% | 4,840 | 1,467 | 2,516 | 2,182 | 4,718 | 1,789 | 2,973 | 934 | 1,720 | 3,965 | 1,809 | -606 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 0.2% | 153,119 | 152,761 | 149,645 | 150,054 | 147,976 | 143,885 | 144,209 | 152,630 | 152,610 | 154,889 | 154,251 | 154,207 | 152,081 | 155,451 | 160,044 | 159,628 | 154,711 | 155,774 | 154,847 | 154,401 | 154,348 |
Current Assets | 16.1% | 43,357 | 37,351 | 34,518 | 34,711 | 32,027 | 30,122 | 30,170 | 37,422 | 35,393 | 36,134 | 25,487 | 25,011 | 25,554 | 27,799 | 34,557 | 34,880 | 30,877 | 29,845 | 21,168 | 20,709 | 21,136 |
Cash Equivalents | 8.5% | 8,484 | 7,822 | 8,497 | 9,585 | 7,935 | 5,924 | 7,117 | 4,468 | 4,469 | 5,123 | 3,540 | 3,878 | 6,544 | 4,157 | 5,406 | 7,185 | 4,452 | - | 4,577 | 3,610 | 4,976 |
Inventory | -18.0% | 4,630 | 5,645 | 4,416 | 4,514 | 4,211 | 4,777 | 4,017 | 3,781 | 3,500 | 3,722 | 3,020 | 3,042 | 2,919 | 3,165 | 2,657 | 2,712 | 2,565 | 2,661 | 2,160 | 2,298 | 2,382 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4,417 | 4,448 | 4,538 | 4,523 |
Goodwill | 0.0% | 44,258 | 44,259 | 45,810 | 45,811 | 45,811 | 45,811 | 45,807 | 45,810 | 45,804 | 45,811 | 46,056 | 46,063 | 44,635 | 44,648 | 44,685 | 44,590 | 44,584 | 44,602 | 44,462 | 44,449 | 44,537 |
Liabilities | 5.0% | 111,769 | 106,410 | 103,879 | 104,528 | 103,380 | 99,131 | 99,076 | 106,663 | 106,446 | 107,705 | 106,768 | 105,440 | 103,867 | 105,065 | 111,946 | 112,223 | 109,590 | 110,395 | 110,114 | 110,552 | 111,897 |
Current Liabilities | 6.7% | 51,977 | 48,716 | 47,059 | 47,345 | 44,727 | 41,225 | 41,115 | 45,218 | 43,662 | 43,572 | 36,340 | 34,711 | 33,470 | 36,022 | 43,886 | 42,179 | 40,380 | 40,138 | 34,447 | 31,867 | 32,969 |
Long Term Debt | 10.3% | 31,053 | 28,155 | 28,094 | 28,115 | 29,124 | 28,100 | 28,090 | 30,984 | 31,013 | 31,125 | 31,609 | 31,606 | 31,568 | 29,545 | 29,537 | 31,774 | 32,147 | 31,893 | 34,041 | 36,885 | 37,571 |
Shareholder's Equity | -10.5% | 41,350 | 46,223 | 45,691 | 45,464 | 44,518 | 44,675 | 44,806 | 45,701 | 46,145 | 46,976 | 47,427 | 48,716 | 48,155 | 50,189 | 48,039 | 47,371 | 45,086 | 45,344 | 44,699 | 43,818 | 42,413 |
Retained Earnings | -1.6% | 40,978 | 41,652 | 40,982 | 39,936 | 38,841 | 37,940 | 37,041 | 34,626 | 33,420 | 32,593 | 31,803 | 30,513 | 29,389 | 28,575 | 24,440 | 23,052 | 21,298 | 20,162 | 19,185 | 17,834 | 16,426 |
Additional Paid-In Capital | -1.2% | 30,292 | 30,669 | 30,563 | 30,436 | 30,332 | 30,233 | 29,395 | 29,930 | 29,736 | 29,574 | 29,077 | 29,403 | 29,254 | 28,975 | 28,777 | 28,699 | 28,554 | 28,306 | 28,115 | 27,891 | 27,855 |
Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 372 | 373 | 378 | 379 |
Minority Interest | 704.8% | 169 | 21.00 | 11.00 | 19.00 | 16.00 | 13.00 | 42.00 | 30.00 | 22.00 | 18.00 | 12.00 | 7.00 | 6.00 | 7.00 | 7.00 | 5.00 | 7.00 | 6.00 | 3.00 | 3.00 | 5.00 |
Float | - | - | - | - | 82,800 | - | - | - | 82,800 | - | - | - | 80,800 | - | - | - | 68,900 | - | - | - | 59,400 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 229.9% | 4,840 | 1,467 | 2,826 | 2,492 | 5,028 | 2,099 | 3,283 | 1,244 | 2,030 | 4,275 | 2,119 | -296 | 1,093 | 4,294 | 895 | 3,274 | 1,887 | 2,793 | 2,461 | 1,039 | 3,192 |
Cashflow From Investing | -12.5% | -495 | -440 | -1,337 | -414 | -2,983 | -616 | 4,446 | -408 | -324 | 123 | -710 | -2,307 | -717 | 4,420 | -938 | -237 | -269 | -271 | -304 | -634 | 475 |
Cashflow From Financing | -102.3% | -2,529 | -1,250 | -2,572 | -435 | -37.00 | -2,636 | -5,517 | -916 | -2,171 | -2,371 | -1,728 | -62.00 | -4,051 | -4,721 | -1,682 | -312 | -1,818 | -1,707 | -1,173 | -1,773 | -2,534 |
Dividend Payments | -100.0% | - | 358 | 362 | 362 | 368 | 334 | 341 | 352 | 357 | 324 | 330 | 342 | 345 | - | - | 15.00 | - | - | - | - | - |
Buy Backs | 639.3% | 4,022 | 544 | 624 | 154 | 962 | 1,733 | 3,500 | 1,006 | 1,368 | 1,421 | 2,611 | 916 | 2,794 | 1,690 | 1,028 | 368 | 956 | 447 | 674 | 404 | 462 |
Consolidated Statements of Income - USD ($) $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues | ||
Premiums | $ 11,603 | $ 11,025 |
Net investment income | 290 | 277 |
TOTAL REVENUES | 57,255 | 46,517 |
Benefits and expenses | ||
Pharmacy and other service costs | 41,431 | 31,459 |
Medical costs and other benefit expenses | 9,440 | 9,046 |
Selling, general and administrative expenses | 3,705 | 3,538 |
Amortization of acquired intangible assets | 423 | 459 |
TOTAL BENEFITS AND EXPENSES | 54,999 | 44,502 |
Income from operations | 2,256 | 2,015 |
Interest expense and other | (322) | (358) |
Loss on sale of businesses | (19) | 0 |
Net realized investment losses | (1,836) | (56) |
Income before income taxes | 79 | 1,601 |
TOTAL INCOME TAXES | 291 | 295 |
Net (loss) income | (212) | 1,306 |
Less: Net income attributable to noncontrolling interests | 65 | 39 |
SHAREHOLDERS' NET (LOSS) INCOME | $ (277) | $ 1,267 |
Shareholders' net (loss) income per share | ||
Basic (in dollars per share) | $ (0.97) | $ 4.28 |
Diluted (in dollars per share) | $ (0.97) | $ 4.24 |
Pharmacy revenues | ||
Revenues | ||
Revenues | $ 42,036 | $ 32,144 |
Fees and other revenues | ||
Revenues | ||
Revenues | $ 3,326 | $ 3,071 |
Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 | ||
---|---|---|---|---|
Assets | ||||
Cash and cash equivalents | $ 8,439 | $ 7,822 | ||
Investments | 1,108 | 925 | ||
Accounts receivable, net | 20,563 | 17,722 | ||
Inventories | 4,630 | 5,645 | ||
Other current assets | 2,263 | 2,169 | ||
Assets of businesses held for sale | 6,354 | 3,068 | ||
Total current assets | 43,357 | 37,351 | ||
Long-term investments | 16,025 | 17,985 | ||
Reinsurance recoverables | 4,672 | 4,835 | ||
Property and equipment | 3,607 | 3,695 | ||
Goodwill | 44,258 | 44,259 | ||
Other intangible assets | 30,491 | 30,863 | ||
Other assets | 3,293 | 3,421 | ||
Separate account assets | 7,416 | 7,430 | ||
Assets of businesses held for sale, non-current | 0 | 2,922 | ||
TOTAL ASSETS | 153,119 | 152,761 | ||
Liabilities | ||||
Current insurance and contractholder liabilities | 5,788 | 5,514 | ||
Pharmacy and other service costs payable | 24,284 | 19,815 | ||
Accounts payable | 8,118 | 8,553 | ||
Accrued expenses and other liabilities | 8,857 | 9,955 | ||
Short-term debt | 1,715 | 2,775 | ||
Liabilities of businesses held for sale | 3,215 | 2,104 | ||
Total current liabilities | 51,977 | 48,716 | ||
Non-current insurance and contractholder liabilities | 10,641 | 10,904 | ||
Deferred tax liabilities, net | 7,029 | 7,173 | ||
Other non-current liabilities | 3,653 | 3,441 | ||
Long-term debt | 31,053 | 28,155 | ||
Separate account liabilities | 7,416 | 7,430 | ||
Liabilities of businesses held for sale, non-current | 0 | 591 | ||
TOTAL LIABILITIES | 111,769 | 106,410 | ||
Contingencies — Note 16 | ||||
Redeemable noncontrolling interests | 0 | 107 | ||
Shareholders' equity | ||||
Common stock | [1] | 4 | 4 | |
Additional paid-in capital | 30,292 | 30,669 | ||
Accumulated other comprehensive loss | (2,324) | (1,864) | ||
Retained earnings | 40,978 | 41,652 | ||
Less: Treasury stock, at cost | (27,769) | (24,238) | ||
TOTAL SHAREHOLDERS' EQUITY | 41,181 | 46,223 | ||
Other noncontrolling interests | 169 | 21 | ||
Total equity | 41,350 | 46,244 | ||
Total liabilities and equity | $ 153,119 | $ 152,761 | ||
|
 | Mr. David Michael Cordani |
---|---|
 | cigna.com |
 | Healthcare Plans |
 | 65535 |